|
KMID : 1142020230580040208
|
|
Blood Research
2023 Volume.58 No. 4 p.208 ~ p.220
|
|
|
A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
|
|
Lee Yong-Pyo
Jung Ye-Ji
Cho Jun-Hun
Ko Young-Hyeh
Kim Won-Seog
Kim Seok-Jin
Yoon Sang-Eun
|
|
|
Abstract
|
|
|
Background While treatment strategies for mantle cell lymphoma (MCL) have evolved, patients often experience disease progression and require additional treatment therapies. Ibrutinib presents a promising option for relapsed or refractory MCL (RR-MCL). This study investigated real-world treatment outcomes of ibrutinib in patients with RR-MCL.
Methods A single-center retrospective analysis investigated clinical characteristics and survival outcomes of patients with RR-MCL, treated with ibrutinib.
Results Forty-two patients were included, with 16 received rituximab and bendamustine, and 26 receiving anthracycline-based regimens as front-line treatment. During a median follow- up of 46.0 months, the response rate to ibrutinib was 69%, with 12 CRs and 8 partial responses. Disease progression (54.8%) and adverse events (11.9%) were the primary reasons for discontinuation. Median progression-free survival (PFS) and overall survival (OS) were approximately 16.4 and 50.1 months, respectively. Patients older than 70 years (P =0.044 and P=0.006), those with splenomegaly (P =0.022 and P =0.006), and those with a high-risk simplified Mantle Cell Lymphoma International Prognostic Index (sMIPI) (P ＜0.001 and P ＜0.001) exhibited siginificantly inferior PFS and OS. Notably, patients with a high-risk sMIPI relapsed earlier. Post-ibrutinib treatment yilded an OS of 12.2 months, while clinical trial participants demonstrated superior survival compared to those receiving chemotherapy alone.
Conclusion This study underscores the importance of considering patient characteristics before administering ibrutinib as salvage therapy. Early relapse was associated with poor outcomes, highlighting the need for novel therapeutic strategies.
|
|
|
KEYWORD
|
|
|
Ibrutinib, Mantle-cell, Lymphoma, Relapsed or refractory
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|